Novartis gets EU approval for Cushing's drug
ZURICH, April 25
ZURICH, April 25 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX) said on Wednesday it has won European Union approval for its Signifor as the first medical therapy for Cushing's disease, a rare hormonal disorder.
Signifor, which is designed for Cushing's disease patients who cannot have surgery or for whom surgery has not been successful, had already won a green light from the European Medicines Agency (EMA) in January. [ID:nL6E8CK24E]
Cushing's is caused by a small tumour of the pituitary gland making too much of a hormone. Standard treatment is surgical removal of the tumour, but this does not always work.
- Obama makes rare campaign trail appearance, people leave early
- Two arrested in death of Saudi student in California: report
- Turkey to let Iraqi Kurds reinforce Kobani as U.S. drops arms to defenders
- After clashes, Hong Kong students, government stand their ground before talks |
- Solid data, earnings push world stocks higher